drugset

drugset / Trial / NCT00422019

A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

NCT00422019 ↗

Phase 2 Completed 61 enrolled Amgen

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of AMG 102 in patients with Advanced Renal Cancer.

Timeline

Start: 2007-01
Primary completion: 2009-03
Completion: 2009-03

Publications

Background Schoffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep;108(5):679-86. doi: 10.1111/j.1464-410X.2010.09947.x. Epub 2010 Dec 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rilotumumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Rilotumumab	Monoclonal antibody	20 mg/kg	Intravenous

Indications